Start narrow
A good peptide goal is specific enough for clinician review
“I want better health” is too broad for a safe prescribing decision. A more useful goal names the symptom or outcome, the product category, the baseline, the risk question, and how follow-up will judge whether care still makes sense. This keeps the visit centered on medical fit rather than pressure to prescribe.
- For semaglutide, tirzepatide, Wegovy, Ozempic, Zepbound, or Mounjaro, goals often connect weight trend, appetite, GI tolerability, glucose context, medication access, and nutrition support.
- For sermorelin, a clinician must establish an independent medical rationale and review relevant records or labs, glucose risk, contraindications, and state-law requirements. Recovery, body composition, bodybuilding, strength, and performance are not eligible goals.
- For PT-141, NAD+, glutathione, GHK-Cu, and methylene blue, goals should stay tied to route, evidence limits, interactions, side effects, and whether the expected benefit is actually measurable.